Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025.

Exceptional itemResults View source PDF Explain this filing

NH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.5%Reaction day

₹1943.00

prior close

₹1915.50

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+1.0%-6.4% vs market

Hospital peers, median of 18sector+0.2%-5.6% vs sector

On the reaction day the stock moved 6.4 pts less than Nifty Smallcap 250 and 5.6 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.3

10m

-2.2

15m

-2.6

30m

-3.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.5+1.0-6.4+0.2-5.6

Next day

-6.9+0.7-7.6+0.7-7.6

-9.3-0.6-8.7-0.2-9.1

-8.6-0.7-8.0+0.0-8.6

-10.7-1.9-8.7-1.7-8.9

-8.8-1.5-7.3-0.8-8.0

-5.7-0.8-4.9+2.3-8.0

15d

-8.4-0.7-7.7-0.2-8.2

-5.7+0.0-5.7+0.9-6.6

-8.0+1.0-9.0+4.1-12.1

-5.7+2.7-8.4+2.7-8.3

UpDownMarket · Nifty Smallcap 250Sector · Hospital peers, median of 18Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Narayana Hrudayalaya reported its Q1 FY26 (quarter ended June 30, 2025) results. Consolidated revenue from operations grew about 15.4% year-on-year to ₹1,507 crore, while standalone revenue grew about 8.2% to ₹943 crore. Consolidated EBITDA was ₹361 crore against ₹326 crore in Q1 FY25, and net profit stood at ₹197 crore versus ₹201 crore, essentially flat. Standalone net profit rose marginally to ₹87 crore from ₹86 crore. The Board also approved seeking shareholder approval to raise up to ₹2,500 crore in debt securities (including NCDs) on a private placement basis, a higher limit than before. Additionally, the scheme to merge subsidiary Meridian Medical Research & Hospital Ltd. with the company received 'No Observation' letters from BSE and NSE and will now move to the NCLT. Deloitte Haskins & Sells LLP issued an unqualified limited review report on both sets of results.

Likely market impact

The proposed ₹2,500 crore debt raise is the key development for shareholders, as it could materially increase leverage (current debt-to-equity is 0.65 standalone, 0.58 consolidated) depending on drawdowns. Operating performance is steady with mid-teens consolidated revenue growth, but margin and profit growth have been muted, partly due to the Vaishno Devi hospital being classified as discontinued operations.